

ASX Release

TALi Digital Expert Advisory Board Update

TALi Digital Ltd (ASX:TD1, "TALi" or "the Company") a leading medical device and technology business seeking to improve attention in early childhood has today announced new appointments to its Expert Advisory Board, welcoming Ms Sarah Michel and Dr Phil Lambert, together with Professor Con Stough and Dr Scott Kollins as scientific advisors.

The Expert Advisory Board is entrusted with instilling the highest standards of academic rigour and frontline experience to TALi's work. They will meet on a regular basis with the team and Board to provide feedback on key matters pertaining to the collection and translation of clinical evidence, and to inform the ongoing development of the TALi technology platform. They will also help to cultivate local and international academic and commercial partnerships.

TALi Digital Non-Executive Chair, Sue MacLeman, said: "We are delighted to have attracted advisors with world-leading experience in childhood attention disorders to join our global TALi Expert Advisory Board. It marks a shift in how our Advisory Board operates by balancing scientific excellence with commercial acumen. The Board will assist with guiding our scientific programs and support the team as we grow and scale in major markets. Their expertise will be valuable as we commercialise our digital therapeutic platform, TALi, and in the further expansion of our product pipeline."

Professor Con Stough will support the expansion of research capabilities within the TALi team and is based in Melbourne, Australia. He is a Professor of Cognitive Neuroscience and Psychology at Swinburne University of Technology. Professor Stough has had numerous research leadership roles at Swinburne including the Director of the Brain Sciences Institute (BSI). He is an expert in cognition and human intelligence across the lifespan receiving more than 50 Government and industry grants. He uses his knowledge of human cognition to conduct randomised clinical trials to examine ways to improve cognition, intelligence and well-being. These interventions include cognitive, pharmacological and psychological interventions and have involved measures of attention across all ages from children to the elderly and in several patient groups. He has also conducted trials in the area of attentional difficulties in children and adolescents and is currently leading a consortium of schools measuring and developing emotional intelligence in Australia and New Zealand.

On joining the Advisory Board, Professor Con Stough, said: "Difficulties in attentional processes are common in children and devastating for educational attainment. Joining the TALi Advisory Board is a unique opportunity to contribute to an evidence-based company that could improve the lives and future of many children."

For personal use only

Dr Phil Lambert will support the growth of TALi in the education sector and is based in Sydney, Australia. He has extensive experience in education as a teacher, school principal, inspector, Executive Director, Assistant Director-General, Regional Director (Schools), Sydney and General Manager. He also has specialist experience in curriculum development and led the development of Australia's first national curriculum. Dr Lambert is currently supporting curriculum reform efforts in Japan, as an expert advisor and researcher for its Innovative Schools Network (ISN) initiative and member of the ISN Advisory Board. Dr Lambert is also Curriculum Expert to the OECD Education 2030 Learning Framework project and was recently engaged by the Education Ministries of The Netherlands, Qatar, Kazakhstan and Lithuania to train senior curriculum, assessment and supervisory policy officers to support the implementation of their respective national curriculum reforms.

TALi Advisory Member, Dr Phil Lambert said: "I look forward to contributing to what I see as an innovative and authentic approach through TALi's technology platform to improve the engagement and learning skills of students with additional needs."

Ms Sarah Michel, MPH, PMP brings her global experience in the commercialisation of evidence-based health innovations to the Advisory Board. Based in Texas in the United States of America (USA), Sarah will act on behalf of TALi to increase its footprint in both advisory and business development capacities in the USA. She is an experienced life sciences manager and entrepreneur with a demonstrated history of working in the higher education industry. Ms Michel's experience has included strategically planning and managing global health technology projects, as well as budgets within diverse grant portfolios with multiple non-governmental organisations (NGOs). Ms Michel is currently engaged at Rice University in the Department of Medical Innovation to lead global collaborations with government and industry.

Newly appointed TALi Advisory member, Ms Sarah Michel, said: "I look forward to expanding TALi's global footprint in their efforts to help every child reach their potential."

Dr Scott Kollins from the Duke University School of Medicine based in the U.S. will lend his expertise and thought leadership to support TALi's evidence generation strategy. Dr Kollins is a Professor in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine, based in Durham, North Carolina. Dr Kollins also serves as the Global Lead for ADHD and Substance Use Disorders at the Duke Clinical Research Institute and the Director of the Duke ADHD Program. Dr Kollins received his undergraduate degree in psychology from Duke University, and his graduate degree in Clinical Psychology from Auburn University. Dr Kollins has published more than 150 scientific papers and his research has been supported by seven different U.S. federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, FDA, and EPA.

On joining the Advisory Board, Dr Scott Kollins, said: "I look forward to working with TALi's leadership to help to broaden the company's evidence generation strategy, focusing specifically

For personal use only

on the development of studies to investigate the psychometric validity of the TALi DETECT platform and the efficacy of TALi TRAIN.”

The TALi Digital Advisory Board will meet once per quarter and work closely with the TALi management team and Board to support their specific projects.

Release authorised by:

Glenn Smith
TALi Digital Managing Director

ABOUT TALi DIGITAL

TALi Digital Limited (ASX:TD1) a leading medical device and technology business is seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills. Learn more at talihealth.com.

CONTACT

General + Investor Enquiries

Glenn Smith
TALi Digital Managing Director
p. 1300 082 013
e. info@talihealth.com

Media enquiries

Haley Chartres
HACK Director
p. +61 423 139 163
e. haley@hck.digital

For personal use only